H.C. Wainwright analyst Yi Chen raised the firm’s price target on Belite Bio to $60 from $59 and keeps a Buy rating on the shares following the Q2 report. The firm continues to believe that the once daily oral dosing regimen should facilitate market adoption of tinlarebant if approved.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- BLTE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Belite Bio Advances Novel Retinal Disease Treatment
- Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Belite Bio reports Q2 EPS (26c), consensus (25c)
- Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference